Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) Fair Value & Analysis
Healthcare · CN · Market cap 20.8B CNY (≈ $3.1B) · ISIN CNE1000051J4
What is Shanghai Haoyuan Chemexpress Co. Ltd. A really worth?
A solid business, but trading 279% above our fair value of ¥23.47.
Strengths
Risks
For context
Fair value as of: Aug 26, 2026
From 26 valuation models · updated 10 days ago
Share price +10.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥29.65). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 26, 2026.
How to read this chart
60‑month range ¥17.88 – ¥147.55 · fair‑value band ¥17.04 – ¥29.65 · the ¥88.83 price screens above the ¥23.47 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 26, 2026.
Analysis
Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) currently trades at ¥88.83, while our model-based Fair Value estimate is ¥23.47, implying the stock looks roughly 278.5% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ¥53.98 per share, and 0 of the 26 models we run sit above the ¥88.83 price. Bear case: the Dividend Discount group reads lowest at ¥5.89, and 26 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Shanghai Haoyuan Chemexpress Co. Ltd. A generated revenue of 3.0B CNY at a net margin of 8.2%. Revenue grew 20.2% year over year. It earns a return on equity of 7.5%. Net debt stands at 268M CNY. Fundamentals as of Aug 26, 2026
Our scenario range runs from ¥17.04 (bear case) to ¥29.65 (bull case); at ¥88.83, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 2% below its 52-week high and 109% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −74%, 688131 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.6226 per share, which is 2.7 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth Earnings (¥53.98) versus Dividend Discount (¥5.89). Highest evidence: FCF DCF (75).
Notify me when 688131 reaches fair value
Put 688131 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 26, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 75
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. The company offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Haoyuan Chemexpress Co. Ltd. A reported revenue of 2.9B CNY in FY2025 versus 969M CNY in FY2021, a compound +31.2%/yr. Reported net income was 248M CNY in FY2025, compounding +6.7%/yr from FY2021.
of which total revenue +43.3 % · buybacks/dilution −25.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
688131 screens 279% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Shanghai Haoyuan Chemexpress Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) overvalued or undervalued?
What is the fair value of 688131?
What is the quality score of 688131?
What is the revenue of Shanghai Haoyuan Chemexpress Co. Ltd. A (688131)?
What is the net profit margin of 688131?
Does Shanghai Haoyuan Chemexpress Co. Ltd. A pay a dividend?
Watch Shanghai Haoyuan Chemexpress Co. Ltd. A in the live analysis
One click puts Shanghai Haoyuan Chemexpress Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.